AU2017277810A1 - Negative feedback regulation of HIV-1 by gene editing strategy - Google Patents

Negative feedback regulation of HIV-1 by gene editing strategy Download PDF

Info

Publication number
AU2017277810A1
AU2017277810A1 AU2017277810A AU2017277810A AU2017277810A1 AU 2017277810 A1 AU2017277810 A1 AU 2017277810A1 AU 2017277810 A AU2017277810 A AU 2017277810A AU 2017277810 A AU2017277810 A AU 2017277810A AU 2017277810 A1 AU2017277810 A1 AU 2017277810A1
Authority
AU
Australia
Prior art keywords
hiv
nucleic acid
ltr
promoter
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017277810A
Other languages
English (en)
Other versions
AU2017277810A2 (en
Inventor
Wenhui Hu
Rafal Kaminski
Kamel Khalili
Thomas MALCOLM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of AU2017277810A1 publication Critical patent/AU2017277810A1/en
Publication of AU2017277810A2 publication Critical patent/AU2017277810A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU2017277810A 2016-06-03 2017-05-26 Negative feedback regulation of HIV-1 by gene editing strategy Abandoned AU2017277810A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662345549P 2016-06-03 2016-06-03
US62/345,549 2016-06-03
US201662394334P 2016-09-14 2016-09-14
US62/394,334 2016-09-14
PCT/US2017/034763 WO2017213896A1 (en) 2016-06-03 2017-05-26 Negative feedback regulation of hiv-1 by gene editing strategy

Publications (2)

Publication Number Publication Date
AU2017277810A1 true AU2017277810A1 (en) 2018-12-06
AU2017277810A2 AU2017277810A2 (en) 2019-01-03

Family

ID=60578255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277810A Abandoned AU2017277810A1 (en) 2016-06-03 2017-05-26 Negative feedback regulation of HIV-1 by gene editing strategy

Country Status (7)

Country Link
EP (1) EP3463290A4 (zh)
JP (1) JP2019517503A (zh)
CN (1) CN109640946A (zh)
AU (1) AU2017277810A1 (zh)
CA (1) CA3026332A1 (zh)
RU (1) RU2018144877A (zh)
WO (1) WO2017213896A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3918071A1 (en) * 2019-02-01 2021-12-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions targeting virus genomes
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105105B (fi) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
CA2573702C (en) * 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
EP1942192A1 (en) * 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Use of a tailored recombinase for the treatment of retroviral infections
KR102531576B1 (ko) * 2012-12-06 2023-05-11 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
EA037850B1 (ru) * 2013-08-29 2021-05-27 Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Способы и композиции для рнк-направленного лечения вич-инфекции
RU2016136977A (ru) * 2014-02-18 2018-03-20 Дьюк Юниверсити Композиции для инактивации репликации вируса и способы их получения и применения
US20180334732A1 (en) * 2014-11-25 2018-11-22 Drexel University Compositions and methods for hiv quasi-species excision from hiv-1-infected patients
MA41382A (fr) * 2015-03-20 2017-11-28 Univ Temple Édition génique basée sur le système crispr/endonucléase à induction par tat

Also Published As

Publication number Publication date
CN109640946A (zh) 2019-04-16
RU2018144877A (ru) 2020-07-09
JP2019517503A (ja) 2019-06-24
WO2017213896A1 (en) 2017-12-14
CA3026332A1 (en) 2017-12-14
AU2017277810A2 (en) 2019-01-03
EP3463290A4 (en) 2019-10-30
EP3463290A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
AU2017277810A1 (en) Negative feedback regulation of HIV-1 by gene editing strategy
US20200392487A1 (en) Excision of retroviral nucleic acid sequences
US20230193257A1 (en) Tat-induced crispr/endonuclease-based gene editing
US20200282025A1 (en) Methods and compositions for rna-guided treatment of hiv infection
US20190367910A1 (en) Methods and compositions for rna-guided treatment of hiv infection
US20190083656A1 (en) Methods and compositions utilizing cpf1 for rna-guided gene editing
US20200140865A1 (en) An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
US20190085326A1 (en) Negative feedback regulation of HIV-1 by gene editing strategy
US20210060138A1 (en) CRISPR and LASER ART Eliminates HIV
WO2022256516A9 (en) Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 DEC 2018

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period